Home/Pipeline/DYNE-101

DYNE-101

Myotonic Dystrophy Type 1 (DM1)

Phase 1/2ActiveNCT05481879

Key Facts

Indication

Myotonic Dystrophy Type 1 (DM1)

Phase

Phase 1/2

Status

Active

Company

Dyne Therapeutics

About Dyne Therapeutics

Dyne Therapeutics is focused on developing life-transforming therapies for patients with genetically driven muscle diseases through its proprietary FORCE™ (Fragment, Oligonucleotide, Conjugate) platform. This platform enables the targeted delivery of therapeutic payloads to muscle tissue, addressing the root cause of diseases with high unmet need. The company has rapidly advanced multiple candidates into clinical development, with promising early data demonstrating target engagement and biomarker correction. Dyne's strategic approach combines validated oligonucleotide modalities with tissue-specific targeting to overcome historical delivery challenges in muscle disorders.

View full company profile

Therapeutic Areas

Neuromuscular Diseases Rare Diseases Genetic Disorders

Other Myotonic Dystrophy Type 1 (DM1) Drugs

Drug	Company	Phase	Status
AOC Program	Avidity Biosciences	Clinical	Active
GeneTAC Platform for DM1	Design Therapeutics	Preclinical	Active
ENTR-701	Entrada Therapeutics	Preclinical	Active
PGN-EDODM1	PepGen	Phase 2	Recruiting